Kang H, Kim C, Lee H, Rho J G, Seo J-W, Nam J-W, Song W K, Nam S W, Kim W, Lee E K
Department of Biochemistry, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Department of Molecular Science and Technology, Ajou University, Suwon, South Korea.
Cell Death Differ. 2016 Mar;23(3):484-95. doi: 10.1038/cdd.2015.116. Epub 2015 Sep 4.
p130Cas regulates cancer progression by driving tyrosine receptor kinase signaling. Tight regulation of p130Cas expression is necessary for survival, apoptosis, and maintenance of cell motility in various cell types. Several studies revealed that transcriptional and post-translational control of p130Cas are important for maintenance of its expression and activity. To explore novel regulatory mechanisms of p130Cas expression, we studied the effect of microRNAs (miRs) on p130Cas expression in human breast cancer MCF7 cells. Here, we provide experimental evidence that miR-362-3p and miR-329 perform a tumor-suppressive function and their expression is downregulated in human breast cancer. miR-362-3p and miR-329 inhibited cellular proliferation, migration, and invasion, thereby suppressing tumor growth, by downregulating p130Cas. Ectopic expression of p130Cas attenuated the inhibitory effects of the two miRs on tumor progression. Relative expression levels of miR-362-3p/329 and p130Cas between normal and breast cancer correlated inversely; miR-362-3p/329 expression was decreased, whereas that of p130Cas increased in breast cancers. Furthermore, we showed that downregulation of miR-362-3p and miR-329 was caused by differential DNA methylation of miR genes. Enhanced DNA methylation (according to methylation-specific PCR) was responsible for downregulation of miR-362-3p and miR-329 in breast cancer. Taken together, these findings point to a novel role for miR-362-3p and miR-329 as tumor suppressors; the miR-362-3p/miR-329-p130Cas axis seemingly has a crucial role in breast cancer progression. Thus, modulation of miR-362-3p/miR-329 may be a novel therapeutic strategy against breast cancer.
p130Cas通过驱动酪氨酸受体激酶信号传导来调节癌症进展。严格调控p130Cas的表达对于多种细胞类型的存活、凋亡及细胞运动性的维持是必要的。多项研究表明,p130Cas的转录和翻译后调控对于维持其表达和活性很重要。为了探索p130Cas表达的新型调控机制,我们研究了微小RNA(miR)对人乳腺癌MCF7细胞中p130Cas表达的影响。在此,我们提供实验证据表明,miR-362-3p和miR-329发挥肿瘤抑制功能,且它们在人乳腺癌中的表达下调。miR-362-3p和miR-329通过下调p130Cas抑制细胞增殖、迁移和侵袭,从而抑制肿瘤生长。p130Cas的异位表达减弱了这两种miR对肿瘤进展的抑制作用。正常组织和乳腺癌之间miR-362-3p/329与p130Cas的相对表达水平呈负相关;在乳腺癌中,miR-362-3p/329表达降低,而p130Cas表达增加。此外,我们表明miR-362-3p和miR-329的下调是由miR基因的差异DNA甲基化引起的。DNA甲基化增强(根据甲基化特异性PCR)导致乳腺癌中miR-362-3p和miR-329的下调。综上所述,这些发现表明miR-362-3p和miR-329作为肿瘤抑制因子具有新作用;miR-362-3p/miR-329-p130Cas轴似乎在乳腺癌进展中起关键作用。因此,调节miR-362-3p/miR-329可能是一种针对乳腺癌的新型治疗策略。